Urovant Sciences® Announces Partnership with Thinx Inc. to Help
4.8 (707) · $ 27.50 · In stock
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational camp
Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options
Ontario Tech University's largest gift to date to support research hub for innovative, clean-energy technologies
The Thinx Period Lawsuit Gave Customers $21 Each and a Lot of Unanswered Questions
Urovant Sciences® Announces Partnership with Thinx Inc. to Help
Expanding CHB Treatment Criteria with Nucs as Prelude of Novel () ? - Harry Janssen, MD, PhD
Thinx - Company Profile - Tracxn
Sumitovant's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Alana Darden's Instagram, Twitter & Facebook on IDCrawl
)
